Published in PLoS One on August 07, 2014
Stress, Nutrition, and Intestinal Immune Responses in Pigs - A Review. Asian-Australas J Anim Sci (2016) 0.85
Dietary grape seed proanthocyanidins (GSPs) improve weaned intestinal microbiota and mucosal barrier using a piglet model. Oncotarget (2016) 0.75
Sensory neuron regulation of gastrointestinal inflammation and bacterial host defence. J Intern Med (2017) 0.75
Unravelling the pathogenesis of inflammatory bowel disease. Nature (2007) 18.52
The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol (2009) 13.87
Host-specific fimbrial adhesins of noninvasive enterotoxigenic Escherichia coli strains. Microbiol Rev (1982) 8.90
Culture-independent analysis of gut bacteria: the pig gastrointestinal tract microbiota revisited. Appl Environ Microbiol (2002) 4.26
A synthetic peptide corresponding to the extracellular domain of occludin perturbs the tight junction permeability barrier. J Cell Biol (1997) 3.86
Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev (2000) 3.24
The enteric nervous system. N Engl J Med (1996) 3.02
Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med (2001) 2.81
Escherichia coli in postweaning diarrhea in pigs: an update on bacterial types, pathogenesis, and prevention strategies. Anim Health Res Rev (2005) 2.65
Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol (2009) 2.63
Molecular physiology and pathophysiology of tight junctions. IV. Regulation of tight junctions by extracellular stimuli: nutrients, cytokines, and immune cells. Am J Physiol Gastrointest Liver Physiol (2000) 2.48
Development of a real-time PCR method for Firmicutes and Bacteroidetes in faeces and its application to quantify intestinal population of obese and lean pigs. Lett Appl Microbiol (2008) 2.19
Cytokine regulation of tight junctions. Biochim Biophys Acta (2008) 2.16
The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev (2004) 2.04
The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr Rev (2000) 1.71
The nervous system and innate immunity: the neuropeptide connection. Nat Immunol (2005) 1.63
Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat Rev Immunol (2007) 1.61
Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology (2003) 1.58
Weaning is associated with an upregulation of expression of inflammatory cytokines in the intestine of piglets. J Nutr (2004) 1.50
Occludin regulates macromolecule flux across the intestinal epithelial tight junction barrier. Am J Physiol Gastrointest Liver Physiol (2011) 1.48
Transforming growth factor-beta differentially inhibits MyD88-dependent, but not TRAM- and TRIF-dependent, lipopolysaccharide-induced TLR4 signaling. J Biol Chem (2004) 1.46
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J Immunol (1999) 1.35
The intestinal barrier and its regulation by neuroimmune factors. Neurogastroenterol Motil (2010) 1.32
Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6. J Immunol (1999) 1.26
Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP. Regul Pept (2002) 1.23
Multi-faceted functions of secretory IgA at mucosal surfaces. Front Immunol (2013) 1.19
Human ENS regulates the intestinal epithelial barrier permeability and a tight junction-associated protein ZO-1 via VIPergic pathways. Am J Physiol Gastrointest Liver Physiol (2003) 1.17
The development of the mucosal immune system pre- and post-weaning: balancing regulatory and effector function. Proc Nutr Soc (2005) 1.16
Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1. Am J Pathol (2008) 1.11
Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med (2010) 1.11
Invasive bacterial pathogens exploit TLR-mediated downregulation of tight junction components to facilitate translocation across the epithelium. Cell Host Microbe (2011) 1.10
Cutting edge: is vasoactive intestinal peptide a type 2 cytokine? J Immunol (2001) 1.10
Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. J Mol Med (Berl) (2001) 1.08
Antimicrobial activity of neuropeptides against a range of micro-organisms from skin, oral, respiratory and gastrointestinal tract sites. J Neuroimmunol (2008) 1.08
Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther (2005) 1.07
LPS-induced cytokine levels are repressed by elevated expression of HSP70 in rats: possible role of NF-kappaB. Cell Stress Chaperones (2009) 1.06
Functional VIP receptors in the human mucus-secreting colonic epithelial cell line CL.16E. Am J Physiol (1989) 1.03
T cells, dendritic cells and epithelial cells in intestinal homeostasis. Int J Med Microbiol (2009) 1.03
Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock. Eur J Immunol (2000) 1.02
Performance responses and indicators of gastrointestinal health in early-weaned pigs fed low-protein amino acid-supplemented diets. J Anim Sci (2006) 1.01
Neuropeptides kill African trypanosomes by targeting intracellular compartments and inducing autophagic-like cell death. Cell Death Differ (2008) 0.99
Vasoactive intestinal peptide ameliorates intestinal barrier disruption associated with Citrobacter rodentium-induced colitis. Am J Physiol Gastrointest Liver Physiol (2009) 0.98
Associations between mucosal innate and adaptive immune responses and resolution of diarrheal pathogen infections. Infect Immun (2009) 0.98
Expression of mucin-type glycoprotein K88 receptors strongly correlates with piglet susceptibility to K88(+) enterotoxigenic Escherichia coli, but adhesion of this bacterium to brush borders does not. Infect Immun (1998) 0.97
Chito-oligosaccharide reduces diarrhea incidence and attenuates the immune response of weaned pigs challenged with Escherichia coli K88. J Anim Sci (2010) 0.94
Peptides targeting Toll-like receptor signalling pathways for novel immune therapeutics. Curr Pharm Des (2010) 0.92
Regulation of TLR expression, a new perspective for the role of VIP in immunity. Peptides (2007) 0.91
Diet, microbiome, and the intestinal epithelium: an essential triumvirate? Biomed Res Int (2013) 0.91
Weaned pig responses to Escherichia coli K88 oral challenge when receiving a lysozyme supplement. J Anim Sci (2011) 0.89
Growth performance and gastrointestinal microbial ecology responses of piglets receiving Saccharomyces cerevisiae fermentation products after an oral challenge with Escherichia coli (K88). J Anim Sci (2010) 0.89
VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production. Pancreas (2005) 0.88
Direct and indirect antimicrobial activities of neuropeptides and their therapeutic potential. Curr Protein Pept Sci (2012) 0.88
Pituitary adenylate cyclase-activating polypeptides (PACAP27 and PACAP38) inhibit the mobility of murine thymocytes and splenic lymphocytes: comparison with VIP and implication of cAMP. J Neuroimmunol (1995) 0.85
VIP balances innate and adaptive immune responses induced by specific stimulation of TLR2 and TLR4. Peptides (2008) 0.85
Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in LPS-stimulated macrophages. J Neuroimmunol (2000) 0.85
Mechanism of VIP-stimulated chloride secretion by intestinal epithelial cells. Ann N Y Acad Sci (1988) 0.84
Vasoactive intestinal peptide inhibits IL-8 production in human monocytes by downregulating nuclear factor kappaB-dependent transcriptional activity. Biochem Biophys Res Commun (2003) 0.83
Therapeutic efficacy of stable analogues of vasoactive intestinal peptide against pathogens. J Biol Chem (2014) 0.82
Impact of bioactive substances on the gastrointestinal tract and performance of weaned piglets: a review. Animal (2009) 0.82
VIP modulation of immune cell functions. Adv Neuroimmunol (1996) 0.82
Vasoactive intestinal peptide specifically induces human IgA1 and IgA2 production. Eur J Immunol (1994) 0.82
Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disorders. Peptides (2007) 0.81
Mycoplasma hyopneumoniae induces pro-inflammatory cytokine and nitric oxide production through NFκB and MAPK pathways in RAW264.7 cells. Vet Res Commun (2010) 0.80
Fast acting nervous regulation of immunoglobulin A secretion from isolated perfused porcine ileum. Gut (1999) 0.80
Vasoactive intestinal peptide can modulate immune and endocrine responses during lipopolysaccharide-induced acute inflammation. Neuroimmunomodulation (2004) 0.79
Secretion of immunomodulating neuropeptides (VIP, SP) and nitric oxide synthase in porcine small intestine during postnatal development. Eur J Histochem (2012) 0.78